NClip

Growth Hormones at mga Suppressant

3 min na pagbabasa

Growth Hormones at mga Suppressant

Mahahalagang Punto

  • Sinusuportahan ng growth hormone (somatotropin axis) ang paglaki ng buto, kalamnan, at tissue sa pamamagitan ng IGF-1 signaling.
  • Ginagamit ang somatropin replacement para sa growth-hormone deficiency pathways at piling syndrome-specific indications.
  • Pangunahing ginagamit ang growth-hormone suppressants para sa acromegaly o excess-growth-hormone states.
  • Ang octreotide/lanreotide (somatostatin analogs), bromocriptine (dopamine agonist), at pegvisomant (GH receptor antagonist) ay karaniwang suppressants.
  • Ang core safety priorities ay glucose variability, GI effects, injection-site reactions, hepatic/renal risk contexts, at neuro/mental-status monitoring.

Growth Hormone Replacement

Somatropin

  • Recombinant growth-hormone product na ginagamit para sa failure to grow dahil sa growth-hormone deficiency sa pediatric at adult populations (at piling syndrome-specific protocols gaya ng Prader-Willi pathways).
  • Pinapataas ang IGF-1 signaling upang suportahan ang growth at anabolic tissue effects.
  • Karaniwang ibinibigay sa pamamagitan ng subcutaneous injection na may individualized dosing.

Key interactions

  • Maaaring kontrahin ng glucocorticoids ang growth-promoting effects.
  • Maaaring baguhin ng oral estrogen ang growth-hormone response.
  • Maaaring kailanganing i-adjust ang insulin/oral diabetes medications dahil maaaring magpataas ng blood glucose ang somatropin.

Common adverse effects

  • Injection-site reaction, rash, lipoatrophy, headache.
  • Thyroid-axis suppression at hyperglycemia risk.

Contraindication/caution profile

  • Active malignancy, critical illness, hypersensitivity.
  • Impaired glucose tolerance/diabetes risk contexts.
  • Closed epiphyses sa pediatric growth pathways.

Growth Hormone Suppressants

Drug classes and examples

  • Somatostatin analogs: octreotide, lanreotide.
  • Dopamine agonists: bromocriptine.
  • Growth-hormone receptor antagonist: pegvisomant.

Typical uses

  • Acromegaly kapag hindi sapat o hindi angkop ang surgery/radiation.
  • Piling unresectable tumor syndromes na may hormone-driven symptom burden.

Class-level adverse effects

  • GI symptoms: abdominal pain, nausea, vomiting, diarrhea.
  • Glucose dysregulation: hypo- o hyperglycemia.
  • Fatigue/weakness, vitamin B12 deficiency, injection-site reactions.
  • Organ risk amplification sa severe hepatic o renal impairment contexts.

Notable agent-specific cues

  • Bromocriptine: maaaring magdulot ng nausea, dizziness, drowsiness, constipation, at abdominal cramps; iwasan sa uncontrolled hypertension/hypersensitivity.
  • Lanreotide: kabilang sa interaction concerns ang cyclosporine, bromocriptine, beta blockers; maaaring magdulot ng cholelithiasis at GI symptoms.
  • Octreotide: maaaring magdulot ng gallbladder abnormalities, bradycardia/arrhythmias, hypo- o hyperglycemia, at hypothyroidism; i-monitor nang mabuti kung may history ng cholelithiasis.
  • Pegvisomant: maaaring magkaroon ng liver-test abnormalities at flu-like symptoms; i-monitor ang hepatic safety cues.

Nursing Assessment and Monitoring

  • I-verify ang diagnosis at treatment intent: replacement vs suppression.
  • Panatilihing updated ang medication list at mag-screen para sa hypersensitivity bago ang bawat cycle.
  • I-trend ang glucose at endocrine-lab patterns (kabilang ang IGF-1 kung ordered).
  • I-monitor ang toxicity cues: blurred vision, confusion, persistent GI symptoms, severe headache.
  • Para sa octreotide/lanreotide pathways, i-monitor ang rhythm at gallbladder-related symptom cues kung indicated.
  • Suriin ang mental-health/neuropsychiatric status kapag ang symptom profile o kasabay na therapies ay nagpapataas ng concern.

Patient Education

  • Inumin/i-administer nang eksakto ayon sa reseta; huwag biglang itigil ang therapy nang mag-isa.
  • Iulat ang lumalalang headache, confusion, persistent abdominal pain, severe nausea/vomiting, o injection-site inflammation.
  • Iulat agad ang mood/behavior changes at anumang paglala ng cardiometabolic symptoms.
  • Panatilihin ang follow-up visits at ordered lab draws para sa dose titration at safety monitoring.
  • Huwag gamitin ang mga gamot na ito bilang acute rescue therapy para sa biglaang respiratory distress.
  • endocrine-system - Hormonal regulation framework kabilang ang GH axis physiology.
  • corticosteroids - Glucocorticoid interaction context na maaaring magpahina sa somatropin growth effects.
  • insulin - Glucose-management implications kapag binabago ng GH-pathway drugs ang glycemic control.

Graph View

Mga Backlink